Girges, C;
Vijiaratnam, N;
Athauda, D;
Auld, G;
Gandhi, S;
Foltynie, T;
(2021)
The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability.
Drugs & Aging
, 38
pp. 355-373.
10.1007/s40266-021-00853-7.
Preview |
Text (Accepted manuscript)
Foltynie_Incretin-based_Therapies_Review_CG_24.02.21CA.pdf - Accepted Version Download (335kB) | Preview |
Preview |
Text (Tables)
Foltynie_Tables_for_GLP-1_Review_21.9.2020v2.pdf - Accepted Version Download (119kB) | Preview |
Abstract
The current treatment options for neurodegenerative diseases in older adults rely mainly on providing symptomatic relief. Yet, it remains imperative to identify agents that slow or halt disease progression to avoid the most disabling features often associated with advanced disease stages. A potential overlap between the pathological processes involved in diabetes and neurodegeneration has been established, raising the question of whether incretin-based therapies for diabetes may also be useful in treating neurodegenerative diseases in older adults. Here, we review the different agents that belong to this class of drugs (GLP-1 receptor agonists, dual/triple receptor agonists, DPP-4 inhibitors) and describe the data supporting their potential role in treating neurodegenerative conditions including Parkinson’s disease and Alzheimer’s disease. We further discuss whether there are any distinctive properties among them, particularly in the context of safety or tolerability and CNS penetration, that might facilitate their successful repurposing as disease-modifying drugs. Proof-of-efficacy data will obviously be of the greatest importance, and this is most likely to be demonstrable in agents that reach the central nervous system and impact on neuronal GLP-1 receptors. Additionally, however, the long-term safety and tolerability (including gastrointestinal side effects and unwanted weight loss) as well as the route of administration of this class of agents may also ultimately determine success and these aspects should be considered in prioritising which approaches to subject to formal clinical trial evaluations.
Archive Staff Only
 |
View Item |
